Trials / NCT03073733
Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
Completed Phase 2 Cell therapy
- Sponsor
- jCyte, Inc
- Treatment
- human retinal progenitor cells; Mock injection
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 84 participants
- Started
- 2017-03-01
- Main results expected
- 2020-11-13
- Results posted
- Yes
- Record last updated
- 2024-06-18
What the study is testing
This study evaluates the changes in visual function at 12 months following a single injection of human retinal progenitor cells compared to sham treated controls in a cohort of adult subjects with RP.
Where it runs
United States (3)
- Gavin Herbert Eye Inst, Univ Cal Irvine, Irvine, California
- Retina-Vitreous Associates Medical Group, Los Angeles, California
- Ophthalmic Consultants of Boston, Boston, Massachusetts